SD-RAVEN-INDUSTRIES
15.6.2021 15:17:10 CEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in autonomous agriculture technology, announced today the purchase of a second OMNiPOWER™ platform by Haggerty AgRobotics. Raven’s driverless ag and precision technology deliver impactful solutions for local and enterprise farms as the agriculture industry’s labor shortages continue to grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005181/en/
“Labor shortage concerns within our local growers have really elevated the need for more automation and robotics on the farm,” said Chuck Baresich, President of Haggerty AgRobotics.
Haggerty Creek Ltd., an establised company delivering grain and crop input needs for growers in Ontario, Canada, has been collaborating with Raven to solve industry challenges for over a decade. In 2020, Haggerty Creek Ltd. purchased its first OMNiPOWER and in 2021 purchased OMNiDRIVE to help farmers with operational challenges they face. The growing demand for driverless ag technology as an impactful solution for labor shortages pushed Baresich to launch Haggerty AgRobotics, a service focused entirely on autonomy, robotics and technology automation at the farm level.
The second OMNiPOWER platform will allow Haggerty AgRobotics to lead the industry as one of the first customers to implement a real-world fleet of autonomous machines. Baresich will now manage a fleet of OMNi platforms with machine-to-machine connectivity through the Viper® 4+ field computer. The integration of Raven’s advanced precision farming technology within the OMNiPOWER platform allows for a seamless user experience and real-time shared coverage visibility.
“As one of the first customers of this technology, we are very excited to bring Raven driverless ag solutions to the market in a big way,” said Baresich. “The recent updates and advancements to Raven’s technology are impressive and we have experienced incredible performance in our 2021 spring program. We purchased our second OMNiPOWER platform to continue to be on the leading edge of commercializing autonomous machines as an organized fleet.”
“Raven has made significant investments in our OMNi suite of driverless ag solutions,” said Ben Voss, Raven Applied Technology Director of Sales for North America and Australia. “It is exciting to see a progressive, ag-tech focused operation like Haggerty AgRobotics partner with us to showcase autonomy and precision applications in the agriculture market. OMNiPOWER and OMNiDRIVE position both of us as autonomy pioneers in the global agriculture industry.”
Raven unveiled their OMNi brand of autonomous solutions less than a month ago and is actively fulfilling orders for both OMNiPOWER and OMNiDRIVE™ units worldwide. OMNiPOWER™ is a self-propelled power platform that easily interchanges farm implements like a sprayer or spreader. This autonomous platform empowers ag professionals to perform multiple farm tasks simultaneously without a driver. Raven’s Path to Autonomy begins with precision farming products that reduce driver fatigue and graduates up to full driverless ag technology automation.
By investing in driverless ag technology, Raven continues to design solutions that reduce operating costs, decrease inputs, and improve yields for ag professionals around the world. Available to order today at RavenPrecision.com .
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and lighter-than-air technologies. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, high performance, and unmatched service. For more information, visit https://ravenind.com .
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com .
About Haggerty Creek Ltd.
Haggerty Creek Ltd. was established in 2001 to fill a market need in Ontario’s four counties area, being Lambdon, Middlesex, Elgin and Kent counties. Located north of Bothwell, Ontario, Haggerty Creek provides whole farm solutions, starting with precision crop planning and application, and ending with grain handling and marketing. In response to the growing demand for driverless ag technology, the company launched Haggerty AgRobotics, positioning themselves as a pioneer in a growing industry. Learn more at https://haggertycreek.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005181/en/
Link:
Social Media:
https://www.facebook.com/ravenprecision/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom